Full text not available from this repository.
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||16 Nov 2012 15:28|
|Last Modified:||27 Nov 2013 23:28|
|Publisher:||EMH Swiss Medical Publishers|
|Free access at:||PubMed ID. An embargo period may apply.|
|Citations:||Web of Science®. Times cited: 2|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page